World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
126
Citations
66824
World Ranking
2928
National Ranking
1624

David A. Reardon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David A. Reardon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 697 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David A. Reardon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David A. Reardon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 126 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David A. Reardon is affiliated with Harvard University in the United States. The primary fields of study in their research include Medicine and Biochemistry, Genetics and Molecular Biology. Their work extensively covers subfields such as Genetics, Oncology, Pulmonary and Respiratory Medicine, Immunology, and Molecular Biology.

The main research topics addressed by David A. Reardon are:

  • Glioma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Radiomics and Machine Learning in Medical Imaging
  • Brain Metastases and Treatment
  • Immunotherapy and Immune Responses
  • Cancer Research and Treatments

Key recent papers authored or co-authored by David A. Reardon include:

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma, 2020, JAMA Oncology
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, 2020, Neuro-Oncology
  • Mechanisms and therapeutic implications of hypermutation in gliomas, 2020, Nature
  • Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter, 2022, Neuro-Oncology
  • Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial, 2022, Neuro-Oncology

The scientist frequently collaborates with the following colleagues:

  • Patrick Y. Wen
  • Eudocia Q. Lee
  • Keith L. Ligon
  • Wenya Linda Bi
  • Ugonma Chukwueke

David A. Reardon's research has been published mainly in the following venues:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Neuro-Oncology Advances
  • Clinical Cancer Research
  • ONCOLOGY

Their work is noted for its involvement in oncology with a strong focus on glioma and glioblastoma treatments, integrating immunotherapy approaches and exploring biomarkers. The research contributions also extend to the development of therapeutic strategies involving CAR-T cell therapy and radiomics applied in medical imaging.

Best Publications

  • IDH1 and IDH2 Mutations in Gliomas

    Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    Derin B. Keskin;Annabelle J. Anandappa;Jing Sun;Itay Tirosh

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

    Timothy F. Cloughesy;Aaron Y. Mochizuki;Joey R. Orpilla;Willy Hugo

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

    David A. Reardon;Alba A. Brandes;Antonio Omuro;Paul Mulholland

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • Mechanisms and therapeutic implications of hypermutation in gliomas.

    Mehdi Touat;Mehdi Touat;Mehdi Touat;Yvonne Y. Li;Yvonne Y. Li;Adam N. Boynton;Adam N. Boynton;Liam F. Spurr;Liam F. Spurr

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

    David A. Reardon;Karen L. Fink;Tom Mikkelsen;Timothy F. Cloughesy

  • Molecular targeted therapy of glioblastoma

    Emilie Le Rhun;Matthias Preusser;Patrick Roth;David A. Reardon

  • Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

    Antonio Omuro;Gordana Vlahovic;Michael Lim;Solmaz Sahebjam

  • Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

    Michael R. Zalutsky;David A. Reardon;Gamal Akabani;R. Edward Coleman

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Henry S. Friedman
Henry S. Friedman Duke University
Keith L. Ligon
Keith L. Ligon Harvard University
John H. Sampson
John H. Sampson Duke University
James E. Herndon
James E. Herndon Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Darell D. Bigner
Darell D. Bigner Duke University
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online programs can open new pathways in medicine and healthcare, especially for those seeking flexibility or faster entry into the field. For students looking to enter nursing quickly, fast lpn program options offer streamlined routes to licensure. These courses compress traditional curricula, helping you qualify sooner for hands-on roles in patient care.

Mental health is an area of growing demand. If you hold a master’s degree in nursing, you might consider the fastest post master's pmhnp programs online. These programs let you specialize as a psychiatric mental health nurse practitioner and could expand your career in a critical area of healthcare.

Leadership and administration roles are also accessible with online studies. Pursuing a health care administration online degree can prepare you for managerial positions within clinics, hospitals, or other organizations. If cost is a key concern, search for the cheapest online master degree in healthcare administration to ensure your education is both affordable and impactful.

These online degrees provide flexible and affordable paths to rewarding roles across the healthcare sector.

Best Scientists Citing David A. Reardon

Trending Scientists

Recently Published Articles